Catalyst
Slingshot members are tracking this event:
Top-Line Phase 2 Results from Pluristem's (PSTI) Trial Evaluating PLX-PAD in Intermittent Claudication Due Early 2018
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| PSTI |
|
|
||||
Slingshot Insights Explained
Catalyst Date
Occurred on:
Jun 12, 2018
Occurred Source:
https://globenewswire.com/news-release/2018/06/12/1520101/0/en/Pluristem-Reports-Positive-Top-Line-Results-from-Its-Multinational-Phase-II-Intermittent-Claudication-Study.html
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Top-line Data, Phase 2, Intermittent Claudication, Peripheral Artery Disease
